NASDAQ: CDIOCardio Diagnostics Holdings Inc Stock
$3.84-0.16 (-4%)
Updated May 16, 2025
CDIO Price
$3.84
Fair Value Price
$0.22
Market Cap
$6.67M
52 Week Low
$3.40
52 Week High
$53.10
P/E
-0.41x
P/B
0.7x
P/S
706.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.89k
Earnings
-$8.38M
Gross Margin
100%
Operating Margin
-23,974.82%
Profit Margin
-24,028.2%
Debt to Equity
0.11
Operating Cash Flow
-$5M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CDIO Overview
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CDIO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CDIO
Ranked#252 of 456
Ranked#252 of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important CDIO news, forecast changes, insider trades & much more!
CDIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CDIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDIO ($3.84) is overvalued by 1,658.12% relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CDIO ($3.84) is not significantly undervalued (1,658.12%) relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDIO due diligence checks available for Premium users.
Valuation
CDIO fair value
Fair Value of CDIO stock based on Discounted Cash Flow (DCF)
Price
$3.84
Fair Value
$0.22
Overvalued by
1,658.12%
CDIO ($3.84) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDIO ($3.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
-154.88x
Market
25.95x
CDIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.7x
Industry
4.21x
CDIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDIO's financial health
Profit margin
Revenue
$4.5k
Net Income
-$1.5M
Profit Margin
-33,672.6%
CDIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.6M
Liabilities
$1.1M
Debt to equity
0.11
CDIO's short-term assets ($8.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDIO's short-term assets ($8.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
-$54.6k
Financing
$7.3M
CDIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDIO vs Biotech Stocks
Cardio Diagnostics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.